Patent US5119409A successfully refreshed from Google Patents.
Patent US4248853A successfully refreshed from Google Patents.
US4248853A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay method and kit
Assignee: SmithKline Beecham Corp
•
Filing: 1978-09-08
•
Granted: 1981-02-03
•
Expires: 1998-09-08
Abstract
Abstract Method and materials for determining levels of β-adrenergic blocking drugs in body fluid, the method including the step of measuring inhibition of the binding of β-adrenergic receptor binder to β-adrenergic receptor material caused by β-adrenergic blocking drug present in the body fluid.
Inventors
- 👤 Solomon H. Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 04:05
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/58; G01N33/60; Y; Y10; Y10S; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/815
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
87 words
The method of determining the concentration of β-adrenergic blocking drug and any active metabolites thereof in a body fluid containing same comprising (a) mixing together β-adrenergic receptor material, radioactive β-adrenergic receptor binder and body fluid, and measuring the amount of the radioactive β-adrenergic receptor binder on the β-adrenergic receptor material and (b) mixing together a concentration of a standard amount of non-radioactive β-adrenergic receptor binder, β-adrenergic receptor material and radioactive β-adrenergic receptor binder and measuring the amount of radioactive β-adrenergic receptor binder on the β-adrenergic receptor material.
Claim 2
Independent Claim
87 words
The method of determining the concentration of β-adrenergic blocking drug and any active metabolites thereof in a body fluid containing same comprising (a) mixing together β-adrenergic receptor material, radioactive β-adrenergic receptor binder and body fluid, and measuring the amount of the radioactive β-adrenergic receptor binder on the β-adrenergic receptor material and (b) mixing together a concentration of a standard amount of non-radioactive β-adrenergic receptor binder, β-adrenergic receptor material and radioactive β-adrenergic receptor binder and measuring the amount of radioactive β-adrenergic receptor binder on the β-adrenergic receptor material.
Claim 3
Dependent Claim
48 words
The method of claim 1 in which the material, binder, and body fluid are permitted to remain together a time sufficient to produce sufficient binding of the binder and drug and any active metabolites thereof in the body fluid to said receptor material prior to making the measurement.
Claim 4
Dependent Claim
30 words
The method of claim 1 in which the materials, binder and body fluid are combined in the presence of sufficient buffer to produce a pH of about 6 to 9.
Claim 5
Dependent Claim
26 words
The method of claim 1 in which the receptor material is brain tissue, and the radioactive portion of the binder comprises 3 H or radioactive iodine.
Claim 6
Dependent Claim
14 words
The method of claim 1 in which iodine is 125 I or 131 I.
Claim 7
Independent Claim
98 words
The method of measuring the concentration of β-adrenergic drug and any active metabolites thereof in blood plasma or blood serum containing same which comprises (a) mixing together blood plasma or blood serum with radioactive β-adrenergic receptor binder and β-adrenergic receptor material and measuring the amount of the radioactive β-adrenergic receptor binder on the β-adreneric receptor material and (b) mixing together a concentration of a standard amount of nonradioactive β-adrenergic receptor binder, β-adreneric receptor material and the same radioactive β-adrenergic receptor binder as in (a) and measuring the amount of radioactive β-adrenergic receptor binder on the β-adrenergic receptor material.
Claim 8
Independent Claim
98 words
The method of measuring the concentration of β-adrenergic drug and any active metabolites thereof in blood plasma or blood serum containing same which comprises (a) mixing together blood plasma or blood serum with radioactive β-adrenergic receptor binder and β-adrenergic receptor material and measuring the amount of the radioactive β-adrenergic receptor binder on the β-adreneric receptor material and (b) mixing together a concentration of a standard amount of nonradioactive β-adrenergic receptor binder, β-adreneric receptor material and the same radioactive β-adrenergic receptor binder as in (a) and measuring the amount of radioactive β-adrenergic receptor binder on the β-adrenergic receptor material.
Claim 9
Dependent Claim
41 words
The method of claim 6 in which measuring of the amount of radioactive-adrenergic receptor binder on the β-adrenergic receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radioactive portion of the radioactive binder.
Claim 10
Dependent Claim
35 words
The method of claim 7 in which the concentration of drug and active metabolite is determined by reference to a standard curve representing percent inhibition of radioactive β-adrenergic receptor binder vs. non-radioactive β-adrenergic receptor binder.
Claim 11
Dependent Claim
13 words
The method of claim 1 in which the receptor material is brain tissue.
Claim 12
Dependent Claim
25 words
As a mercantile unit, a kit of at least one container of radioactive β-adrenergic receptor binder, β-adrenergic receptor material and standard non-radioactive β-adrenergic receptor binder.
Claim 13
Dependent Claim
25 words
As a mercantile unit, a kit of at least one container of radioactive β-adrenergic receptor binder, β-adrenergic receptor material and standard non-radioactive β-adrenergic receptor binder.
Claim 14
Dependent Claim
27 words
The kit of claim 10 in which the radioactive β-adrenergic receptor binder is selected from the group consisting of radioactive labelled propranolol practalol pindalol alprenolol sotalol butoxamine.
Claim 15
Dependent Claim
27 words
The method of claim 7 in which unbound drug, unbound radioactive binder and plasma or serum are removed as part of determining the percent inhibition of binding.
Claim 16
Dependent Claim
16 words
The method of claim 1 in which the body fluid is blood plasma or blood serum.
Claim 17
Dependent Claim
22 words
The method of claim 1 in which the concentration of body fluid in the mixture containing same is less than about 10%.
Claim 18
Dependent Claim
22 words
The method of claim 14 in which the amount of body fluid in the mixture containing same is greater than one microliter.
Claim 19
Dependent Claim
26 words
The method of claim 1 in which radioactive β-adrenergic receptor binder is selected from the group consisting of radioactive labelled propranolol practalol pindalol alprenolol sotalol butoxamine.
Claim 20
Dependent Claim
15 words
The method of claim 16 in which the radioactive receptor binder is radioactive labelled propranolol.
Claim 21
Dependent Claim
13 words
The method of claim 6 in which the receptor material is brain tissue.
Claim 22
Dependent Claim
23 words
The kit of claim 11 in which said standard binder is selected from the group consisting of, propranolol practalol pindalol alprenolol sotalol butoxamine.
Claim 23
Dependent Claim
42 words
The method of claim 1 in which measuring of the amount of radioactive β-adrenergic receptor binder on the β-adrenergic receptor material is determined in a gamma detector or scintillation counter based upon the nature of the radioactive portion of the radioactive binder.
Claim 24
Dependent Claim
37 words
The method of claim 1 in which the concentration of drug and metabolite in the blood is determined by reference to a standard curve representing percent inhibtion of radioactive β-adrenergic receptor binder vs. non-radioactive β-adrenergic receptor binder.
Claim 25
Dependent Claim
30 words
The method of claim 1 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 26
Dependent Claim
30 words
The method of claim 6 in which (b) is repeated a sufficient number of times while varying concentration of the non-radioactive binder to provide information for generating a standard curve.
Claim 27
Dependent Claim
17 words
The method of claim 22 in which the radioactive binder is the same in (a) and (b).
References Cited (Backward Citations)
US4026879A
Cited
US4070492A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-02-03 | 1984-08-04 | 1985-02-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-02-03 | 1988-08-04 | 1989-02-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-02-03 | 1992-08-04 | 1993-02-03 | $7700.00 | Window Closed / Lapsed |